Intensification of Vero cell adherence to microcarrier particles during cultivation in a wave bioreactor

被引：0

作者：

Mazhed, Z. K. ^{[1
]}

Vasilenko, V. E. ^{[1
]}

Siniugina, A. A. ^{[1
]}

Kaa, K. V. ^{[1
]}

Motov, A. S. ^{[1
]}

Pokidova, K. O. ^{[1
]}

Ivin, Y. Y. ^{[1
]}

Piniaeva, A. N. ^{[1
]}

Khapchaev, Y. K. ^{[1
]}

Chernov, K. A. ^{[1
]}

Ishmukhametov, A. A. ^{[1
,2
]}

机构：

[1] Russian Acad Sci RAS, Fed State Autonomous Sci Inst FSASI, Chumakov Fed Sci Ctr Res & Dev Immune & Biol Prod, Moscow, Russia

[2] First Moscow State Med Univ Sechenov Univ, Inst Translat Med & Biotechnol, Moscow, Russia

来源：

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY | 2025年 / 13卷

关键词：

cell cultivation; microcarrier particles; bioreactor technology; Vero cells; wave bioreactor; cytodex-1; vaccine production; upstream process development; INACTIVATED VACCINE; GROWTH; STRAINS;

D O I：

10.3389/fbioe.2025.1542060

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Vaccination is the most effective strategy for fighting viral diseases, with both live and inactivated vaccines remaining crucial despite advancements in subunit vaccine technologies. A key player in vaccine production is the Vero cell line, derived from the kidney cells of the African green monkey, which is essential for manufacturing vaccines against diseases like polio, rabies, yellow fever, and COVID-19. The efficiency of Vero cell cultivation directly impacts vaccine production, often utilizing bioreactors ranging from small (1-10 L) to large (up to several thousand liters). Wave-type bioreactors are commonly employed for initial cell propagation due to their simplicity. However, achieving uniform cell distribution on microcarriers in these systems poses challenges. This study aims to evaluate intermittent stirring during the early cultivation stages to enhance Vero cell distribution and growth, potentially improving overall cultivation efficiency.

引用

页数：7

共 18 条

[1]

Bakker W.A.M., Thomassen Y.E., van't Oever A.G., Westdijk J., van Oijen M.G.C.T., Sundermann L.C., Et al., Inactivated polio vaccine development for technology transfer using attenuated sabin poliovirus strains to shift from salk-IPV to sabin-IPV, Vaccine, 29, pp. 7188-7196, (2011)

[2]

Derakhti D., Safiabadi-Tali S., Amoabediny G., Sheikhpour M., Attachment and detachment strategies in microcarrier-based cell culture technology: a comprehensive review, Mater Sci. Eng. C Mater Biol. Appl, 103, (2019)

[3]

Eibl R., Werner S., Eibl D., Bag bioreactor based on wave-induced motion: characteristics and applications, Adv. Biochem. Eng. Biotechnol, 115, pp. 55-87, (2009)

[4]

Kaa K.V., Ignatyev G.M., Sinyugina A.A., Ishmukhametov A.A., Susceptibility of various cell lines to the chikungunya virus and method selection for commercial-scale production of viral material, Biol. Prod. Prev. Diagn. Treat, 23, pp. 111-120, (2023)

[5]

Kiesslich S., Kamen A.A., Vero cell upstream bioprocess development for the production of viral vectors and vaccines, Biotechnol. Adv, 44, (2020)

[6]

Kozlovskaya L.I., Piniaeva A.N., Ignatyev G.M., Gordeychuk I.V., Volok V.P., Rogova Y.V., Et al., Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies, Emerg. Microbes Infect, 10, pp. 1790-1806, (2021)

[7]

Montagnon B.J., Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line, Dev. Biol. Stand, 70, pp. 27-47, (1989)

[8]

Ng Y.-C., Berry J.M., Butler M., Optimization of physical parameters for cell attachment and growth on macroporous microcarriers, Biotechnol. Bioeng, 50, pp. 627-635, (1996)

[9]

Pato T.P., Souza M.C.O., Mattos D.A., Caride E., Ferreira D.F., Gaspar L.P., Et al., Purification of yel-low fever virus produced in Vero cells for inactivated vaccine manufacture, Vaccine, 37, pp. 3214-3220, (2019)

[10]

Piniaeva A., Ignatyev G., Kozlovskaya L., Ivin Y., Kovpak A., Ivanov A., Et al., Immunogenicity and safety of inactivated sabin-strain polio vaccine “poliovacsin”: clinical trials phase i and ii, Vaccines, 9, (2021)

← 1 2 →